Study shows surgery can treat Breast implant associated Anaplastic Large Cell Lymphoma
During the 84th annual conference of ASPS (American Society of Plastic Surgery’s) a new study (carried out by a group of researchers at MD Anderson Cancer Center) with really interesting findings was presented. The study showed that anaplastic large cel lymphoma (BIA-ALCL) associated with breast implants can be diagnosed and treated surgically. The research showed that such rare lymphoma can be treated successfuly.
The title of the study was “Characteristics and Treatment of Advanced Breast Implant Associated Anaplastic Large Cell Lymphoma,” and the team of researcher included Meredith Collins, MD1 , Mark Clemens, MD , Charles E. Butler, MD , Kelly K. Hunt, MD , L. Jeffrey Medeiros, MD , Michelle A. Fanale, MD, Jun Liu, PhD and Roberto N. Miranda, MD.
Dr. Charles E. Butler, a member of the team and President-elect of PSF (The Plastic Surgery Foundation) stated: “Definitive surgery with implant removal and total capsulectomy appears to be the optimal primary treatment for patients with BIA-ALCL. Overall this is a positive message for the rarity and treatability of the disease.”
Its important to notice that FDA is aware of the risks for such lymphomas and works in cooperation with ASPS and PSF in order to record confirmed BIA_ALCL cases. Dr. Mark Clemens, MD, among the authors of the study reports: “In conjunction with The PSF and the FDA, we have been conducting research and analyzing the incidence of BIA-ALCL to develop better understanding and effectively educate patients and physicians. This cutting edge research is an excellent example of the insights and advances that are unveiled at The Meeting. It is evidence of our role working to bring together the most leading-edge clinical information to enhance patient satisfaction and lead the way advancing patient safety.”